{"prompt": "['!', 'NOVARTIS', 'Global Clinical Development - General Medicine', 'QAW039/fevipiprant', 'Clinical Trial Protocol CQAW039A2317 / NCT03226392', 'A 12-week, multicenter, randomized, double-blind, placebo-', 'controlled study to assess the efficacy and safety of', 'QAW039 when added to standard-of-care asthma therapy', 'in patients with uncontrolled asthma', 'Document type:', 'Clinical Trial Protocol', 'EUDRACT number:', '2017-001272-40', 'Version number:', '00 (Original Protocol)', 'Clinical trial phase:', 'III', 'Release date:', '10-May-2017', 'Property of Novartis', 'Confidential', 'May not be used, divulged, published, or otherwise disclosed', 'without the consent of Novartis', 'Clinical Trial Protocol Template Version 3.2 (July 2016)']['Novartis', 'Confidential', 'Page 2', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Table of contents', 'Table of contents', '2', 'List of tables', '5', 'List of figures', '5', 'List of Abbreviations', '6', 'Glossary of terms', '9', 'Protocol summary', '11', '1 Introduction', '15', '1.1', 'Background', '15', '1.2', 'Purpose', '16', '2', 'Study objectives and endpoints', '16', '2.1', 'Objectives and related endpoints', '16', '3', 'Investigational plan', '18', '3.1', 'Study design', '18', '3.2', 'Rationale for study design', '19', '3.3', 'Rationale for dose/regimen, route of administration and duration of treatment', '21', '3.4', 'Rationale for choice of comparator', '21', '3.5', 'Purpose and timing of interim analyses/design adaptations', '21', '3.6', 'Risks and benefits', '21', '4 Population', '22', '4.1', 'Inclusion criteria', '22', '4.2', 'Exclusion criteria', '24', '5 Treatment', '27', '5.1', 'Study treatment', '27', '5.1.1', 'Investigational and control drugs', '27', '5.1.2', 'Additional treatment', '28', '5.2', 'Treatment arms', '28', '5.3', 'Treatment assignment and randomization', '28', '5.4', 'Treatment blinding', '29', '5.5', 'Treating the patient', '29', '5.5.1', 'Patient numbering', '29', '5.5.2', 'Dispensing the study drug', '30', '5.5.3', 'Handling of study and additional treatment', '30', '5.5.4', 'Instructions for prescribing and taking study treatment', '31', '5.5.5', 'Permitted dose adjustments and interruptions of study treatment', '31', '5.5.6', 'Rescue medication', '32']['Novartis', 'Confidential', 'Page 3', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '5.5.7', 'Concomitant medication', '32', '5.5.8', 'Prohibited medication', '34', '5.5.9', 'Emergency breaking of assigned treatment code', '35', '5.6', 'Study completion and discontinuation', '35', '5.6.1', 'Study completion and post-study treatment', '35', '5.6.2', 'Discontinuation of study treatment', '36', '5.6.3', 'Withdrawal of informed consent', '38', '5.6.4', 'Loss to follow-up', '38', '5.6.5', 'Early study termination by the sponsor', '38', '6', 'Visit schedule and assessments', '39', '6.1', 'Information to be collected on screening failures', '47', '6.2', 'Patient demographics/other baseline characteristics', '47', '6.3', 'Treatment exposure and compliance', '47', '6.4', 'Efficacy', '48', '6.4.1', 'Spirometry (Pre-dose FEV1', ')', '48', '6.4.2', 'eDiary for daily asthma symptoms,', 'and rescue', 'medication use', '48', '6.4.3', 'Asthma exacerbations', '50', '6.4.4', 'Appropriateness of efficacy assessments', '51', '6.5', 'Safety', '51', '6.5.1', 'Physical examination', '52', '6.5.2', 'Vital signs', '52', '6.5.3', 'Height and weight', '52', '6.5.4', 'Laboratory evaluations', '52', '6.5.5', 'Electrocardiogram (ECG)', '53', '6.5.6', 'Pregnancy and assessments of fertility', '54', '6.5.7', 'Appropriateness of safety measurements', '54', '6.6', 'Other assessments', '54', '6.6.1', 'Clinical Outcome Assessments (COAs)', '54', '56', '57', '7', 'Safety monitoring', '57', '7.1', 'Adverse events', '57', '7.2', 'Serious adverse events', '59', '7.2.1', 'Definition of SAE', '59', '7.2.2', 'SAE reporting', '60']\n\n###\n\n", "completion": "END"}